|
gptkbp:instanceOf
|
gptkb:drug
anticonvulsant
|
|
gptkbp:approvalYear
|
1999
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N03AX14
|
|
gptkbp:availableOn
|
gptkb:tablet
intravenous solution
oral solution
|
|
gptkbp:bioavailability
|
nearly 100%
|
|
gptkbp:brand
|
gptkb:Keppra
gptkb:Elepsia_XR
gptkb:Spritam
|
|
gptkbp:CASNumber
|
102767-28-2
|
|
gptkbp:category
|
antiepileptic drug
central nervous system agent
pyrrolidone derivative
|
|
gptkbp:chemicalFormula
|
C8H14N2O2
|
|
gptkbp:contraindication
|
hypersensitivity to levetiracetam
|
|
gptkbp:developedBy
|
gptkb:UCB_Pharma
|
|
gptkbp:drugInteraction
|
minimal
|
|
gptkbp:eliminationHalfLife
|
6-8 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:firstSynthesized
|
1997
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Levetiracetam
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
binds to SV2A protein
|
|
gptkbp:metabolism
|
minimal hepatic
|
|
gptkbp:molecularWeight
|
170.21 g/mol
|
|
gptkbp:patentExpired
|
yes
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescribes
|
adults
children
|
|
gptkbp:proteinBinding
|
less than 10%
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
dizziness
fatigue
headache
drowsiness
irritability
|
|
gptkbp:synonym
|
gptkb:ucb_L059
gptkb:LEV
|
|
gptkbp:usedFor
|
epilepsy
myoclonic seizures
tonic-clonic seizures
partial-onset seizures
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Epileptic_Dogs
|
|
gptkbp:bfsLayer
|
6
|